Crohn's Disease Activity Index (CDAI) score of ≥ 220
Confirmed diagnosis of CD at least 90 days prior to Baseline
Endoscopic evidence of mucosal inflammation as documented by an Simple Endoscopic Score for Crohn's Disease (SES-CD) of ≥ 6 for ileocolonic or colonic disease or SES-CD of ≥ 4 for isolated ileal disease.
Demonstrated failure of 1 or more therapy for CD
UC specific:
Confirmed diagnosis of UC at least 90 days prior to Baseline
Active UC with a modified Mayo Score (mMS) of 5 to 9 points and endoscopic subscore (ESS) of 2 to 3
Demonstrated failure of 1 or more therapy for UC
You may not be if
Participants with demonstrated intolerance to p19 IL-23 inhibitors (including risankizumab)
Participants treated with any investigational drug within 30 days or 5 half-lives of the study treatments (whichever is longer) prior to the first dose of study treatment
Participants who received any ATs (biologic or small molecules) prior to first dose of study treatment within the protocol specified time frame
Participants with surgical bowel resection within the past 3 months prior to Baseline
CD specific:
Participants with \>3 prior bowel resections
Participants with previous small bowel resection(s) of combined length \>100 cm
UC specific:
Participants with prior colectomy (total or subtotal)
Participants with extent of disease limited to \< 10 cm of rectum
Clareo Health | Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
